Patent IE-40929-L (IE)
Title: Substituted n-acyl -n''- (3- amino -2-¹cyano-acryloyl)-formamidrazones
IPC: C07D295/145
Filed: 1974-08-23
Abstract: 1441686 Substituted N-acyl-N<SP>11</SP>-(3-amino-2- cyanoacryloyl)-formamidrazones BYK GULDEN LOMBERG CHEMISCHE FABRIK GmbH 22 Aug 1974 [27 Aug 1973] 36914/74 Heading C2C Novel compounds of Formula I and their tautomers and salts with organic and inorganic acids, in which R<SP>1</SP> and R<SP>2</SP> are the same or different and denote a hydrogen atom, a straight chained or branch chained alkyl radical with 1 to 7 carbon atoms, or a cycloalkyl radical with 3 to 6 carbon atoms, in the case of which if one of the radicals R<SP>1</SP> or R<SP>2</SP> denotes hydrogen atom, the other radical has a meaning differing from hydrogen, or in which R<SP>1</SP> and R<SP>2</SP> together denote an alkylene group with 2 to 5 carbon atoms, in which possibly one or more methylene groups can be replaced by -O-, -S- or by the -NR<SP>7</SP> group, R<SP>3</SP> denotes one of the following radicals in which R<SP>4</SP> denotes a hydrogen atom, a straight chained or branch chained alkyl radical with 1 to 14 carbon atoms, in which possibly a methylene group can be replaced by an oxygen atom, a cycloalkyl radical with 3 to 6 carbon atoms, a phenyl radical substituted by straight chained or branch chained alkyl, alkoxy or alkylmercapto groups with 1 to 7 carbon atoms, alkoxycarbonyl groups with 2 to 5 carbon atoms, halogen, trifluoromethyl, nitro and/or cyano groups or unsubstituted, or a phenylalkyl radical in the case of which the alkyl radical is straight chained or branch chained and possesses 1 to 6 carbon atoms, in the case of which the phenyl radical optionally is substituted as above, and in which the alkyl or cycloalkyl radicals may be substituted by a salt-forming basic group, R<SP>5</SP> and R<SP>6</SP> are the same or different and denote a hydrogen atom, a straight chained or branch chained alkyl radical with 1 to 7 carbon atoms, in which possibly a methylene group can be replaced by an oxygen atom, or a cycloalkyl radical with 3 to 6 carbon atoms or R<SP>5</SP>and R<SP>6</SP> together denote an alkylene group with 2 to 5 carbon atoms, in which possibly one or more methylene groups can be replaced by -O-, -S- or by the -NR<SP>7</SP> group, X denotes a sulfur atom, a -NR<SP>7</SP> group or an oxygen atom, Y denotes a sulfur atom or an oxygen atom, and R<SP>7</SP> denotes a hydrogen atom, a straight chained or branch chained alkyl radical with 1 to 7 carbon atoms, possibly substituted by a hydroxy group, or a phenyl radical, possibly substituted by a straight chained or branch chained alkyl- or alkoxy radical, with 1 to 7 carbon atoms, halogen or trifluoromethyl are prepared by one of the following methods (a) a compound of Formula II is reacted with R<SP>1</SP>NHR<SP>2</SP> or (b) a compound of formula IV is reacted with HC(OR) 3 or R<SP>1</SP>COOCH(OR) 2 in presence of an acid anhydride then with H 2 NNHR<SP>3</SP>. Pharmaceutical compositions in conventional forms for oral or parenteral administration and having use in the treatment of gout, cardiac insufficiency and arrhythmia comprise an above novel compound and carrier therefor.
[GB1441686A]